Acumen Pharmaceuticals ABOS Institutional Ownership

Ownership Summary

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) is held by 84 institutional investors per 13F filings through March 2026.

• They owned 72.8% of outstanding stock in March 2026, up from 62.0% the prior quarter.
• They increased total shares held in Acumen Pharmaceuticals by 31.44% from last quarter, and the number of investors in ABOS increased 2.44% annually.
• Of these 84 holders, 51 added to their stakes in Acumen Pharmaceuticals, 15 trimmed positions, and 18 made no changes.
• Institutional investors collectively held 46.0Mn shares in Acumen Pharmaceuticals as of March 2026, up by 11.0Mn shares quarter on quarter, and up 5.04Mn shares year over year.
• RA CAPITAL MANAGEMENT, L.P. holds the largest position in ABOS at 20.99Mn shares as of March 31, 2026, or 33.21% of shares outstanding.
• The biggest buyers of Acumen Pharmaceuticals for the quarter ending March 2026 included RA CAPITAL MANAGEMENT, L.P. (6.06Mn), Alyeska Investment Group, L.P. (1.52Mn), VANGUARD CAPITAL MANAGEMENT LLC (1.51Mn), Ikarian Capital, LLC (799.48K), TWO SIGMA INVESTMENTS, LP (387.59K).
• The largest sellers of Acumen Pharmaceuticals for the quarter ending March 2026 were Laurion Capital Management LP (1.21Mn), FMR LLC (870.15K), JANE STREET GROUP, LLC (52.46K), Goldman Sachs Group Inc (29.02K), Morgan Stanley (22.32K).
• Per Business Quant data, the top 10 holders of Acumen Pharmaceuticals for the quarter ending March 2026 are RA CAPITAL MANAGEMENT, L.P. (20.99Mn), Sands Capital Alternatives, LLC (3.72Mn), Alyeska Investment Group, L.P. (2.45Mn), Franklin Resources Inc (2.31Mn), ADAR1 Capital Management, LLC (2.16Mn), Knollwood Investment Advisory, LLC (1.63Mn), VANGUARD CAPITAL MANAGEMENT LLC (1.51Mn), FMR LLC (1.16Mn), Ikarian Capital, LLC (1.05Mn), Hudson Bay Capital Management LP (968.94K).